Ervebo
E414773
Ervebo is a recombinant, live-attenuated vaccine developed to protect humans against infection by the Zaire ebolavirus.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Ervebo canonical | 2 |
Statements (51)
| Predicate | Object |
|---|---|
| instanceOf |
Ebola vaccine
ⓘ
live-attenuated vaccine ⓘ recombinant vaccine ⓘ vaccine ⓘ |
| hasAdministrationSchedule | single-dose regimen ⓘ |
| hasAdministrationSite | deltoid muscle ⓘ |
| hasATCCode | J07BX02 ⓘ |
| hasClinicalTrialPhase | Phase 3 completed ⓘ |
| hasCommonAdverseEffect |
arthralgia
ⓘ
fatigue ⓘ fever ⓘ headache ⓘ injection site pain ⓘ injection site swelling ⓘ myalgia ⓘ |
| hasComponent |
Zaire ebolavirus glycoprotein
ⓘ
vesicular stomatitis virus glycoprotein G deletion ⓘ |
| hasDeveloper |
Merck & Co.
ⓘ
NewLink Genetics ⓘ Public Health Agency of Canada ⓘ |
| hasDosageForm | suspension for injection ⓘ |
| hasEfficacy | high efficacy against Zaire ebolavirus in clinical trials ⓘ |
| hasGenericName |
rVSV-ZEBOV
ⓘ
rVSV-ZEBOV ⓘ
surface form:
rVSVΔG-ZEBOV-GP
|
| hasIndication |
pre-exposure prophylaxis against Ebola virus disease caused by Zaire ebolavirus
ⓘ
protection of individuals at high risk of exposure to Zaire ebolavirus ⓘ |
| hasMarketingAuthorizationHolder |
Merck & Co.
ⓘ
surface form:
Merck Sharp & Dohme Corp.
|
| hasRegulatoryApproval |
European Commission
ⓘ
Health Canada ⓘ Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
World Health Organization prequalification ⓘ multiple African national regulatory authorities ⓘ |
| hasRouteOfAdministration | intramuscular injection ⓘ |
| hasStorageRequirement | frozen storage ⓘ |
| hasStorageTemperature | -60°C to -80°C (original formulation) ⓘ |
| hasViralVector | recombinant vesicular stomatitis virus ⓘ |
| hasWHOClassification | Ebola Zaire vaccine ⓘ |
| isAttenuated | true ⓘ |
| isIndicatedForAgeGroup | 18 years and older ⓘ |
| isLive | true ⓘ |
| isRecombinant | true ⓘ |
| isReplicationCompetent | true ⓘ |
| isUsedInOutbreakResponse | true ⓘ |
| targetsDisease | Ebola virus disease ⓘ |
| targetsVirus | Zaire ebolavirus NERFINISHED ⓘ |
| wasApprovedInEUOn | 2019-11-11 ⓘ |
| wasApprovedInUSOn | 2019-12-19 ⓘ |
| wasInitiallyDevelopedBy | Public Health Agency of Canada ⓘ |
| wasPrequalifiedByWHOIn | 2019 ⓘ |
| wasUsedInOutbreak |
2014–2016 West Africa Ebola outbreak
ⓘ
2018–2020 Ebola outbreak in the Democratic Republic of the Congo ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.